Development of glypican-3-specific chimeric antigen receptor-modified natural killer cells and optimization as a therapy for hepatocellular carcinoma
Journal of Leukocyte Biology · 13.02.2025 · 117 (2)
DOI: 10.1093/jleuko/qiae144 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Leukocyte Biology, online erschienen am 26.06.2024. Verfasst von Bihui Cao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac Surgery, Guangdong Provincial People's Hospital, Guangdong Cardiovascular Institute, Guangdong Academy of Medical Sciences, Sou…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Glypicans, Liver Neoplasms, Killer Cells, Natural. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Guangzhou Science and Technology Project, Plan on Enhancing Scientific Research in GMU, Science and Technology Development Fund of Macau.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a highly malignant tumor characterized by insidious onset and rapid progression, with limited treatment choices. One treatment modality, chimeric antigen receptor (CAR)-modified natural killer (NK) cell immunotherapy, has shown promise for various cancers. However, the treatment efficacy of CAR-NK cells for HCC remain inferior. In this study, we developed two glypican-3 (GPC3)-specific CAR-NK-92 cell lines (GPC3-CAR-NK) and explored their antitumor efficacy for the treatment of HCC. Significant levels of cytokine production and in vitro cytotoxicity were produced following co-culture of GPC3+ HCC cells with the developed GPC3-CAR-NK cells. GC33-G2D-NK cells with NK cell-specific signaling domains showed better activation and killing abilities than GC33-CD28-NK cells containing T-cell-specific signaling domains. Moreover, GC33-G2D-NK cells efficiently eliminated tumors in cell-derived xenograft and patient-derived xenograft mouse models. In an abdominal metastasis model, intraperitoneally delivered GC33-G2D-NK cells showed better antitumor ability than intravenously injected cells. Finally, the combination of microwave ablation (MWA) with GC33-G2D-NK cell administration showed greater CAR-NK infiltration and tumor regression in ablated tumors than monotherapy alone. These findings indicate that administration of GPC3-CAR-NK cells may be a potential strategy for the treatment of HCC, and regional delivery or their combination with MWA may optimize their efficacy against HCC and may have translational value.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiac Surgery, Guangdong Provincial People's Hospital, Guangdong Cardiovascular Institute, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou 510080, China.
- Department of Guangdong Provincial Key Laboratory of Pathogenesis and Precision Prevention of Heart Disease, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou 510100, China.
- Department of Radiology, Central Laboratory, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, China.
- Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119074, Singapore.
- Department of Guangdong Provincial and Guangzhou Municipal Key Laboratory of Molecular Target and Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.
- Faculty of Health Sciences, MoE Frontiers Science Center for Precision Oncology, University of Macau, Macau SAR 999078, China.
Förderung
- Guangzhou Science and Technology Project
- Plan on Enhancing Scientific Research in GMU
- Science and Technology Development Fund of Macau
- University of Macau
- National Natural Science Foundation of China
Zitieren
APA
Cao, B., Ni, Q., Chen, Z., Yang, S., Zhang, X., Su, H., Zhang, Z., Zhao, Q., Zhu, X., & Liu, M. (2025). Development of glypican-3-specific chimeric antigen receptor-modified natural killer cells and optimization as a therapy for hepatocellular carcinoma. Journal of Leukocyte Biology, 117(2). https://doi.org/10.1093/jleuko/qiae144
Vancouver
Cao B, Ni Q, Chen Z, Yang S, Zhang X, Su H, et al. Development of glypican-3-specific chimeric antigen receptor-modified natural killer cells and optimization as a therapy for hepatocellular carcinoma. Journal of Leukocyte Biology. 2025;117(2). doi:10.1093/jleuko/qiae144
BibTeX
@article{Cao2025,
author = {Cao, Bihui and Ni, Qianqian and Chen, Zhuxin and Yang, Shuo and Zhang, Xinkui and Su, Haotao and Zhang, Zhenfeng and Zhao, Qi and Zhu, Xiaolan and Liu, Manting},
title = {Development of glypican-3-specific chimeric antigen receptor-modified natural killer cells and optimization as a therapy for hepatocellular carcinoma},
journal = {Journal of Leukocyte Biology},
year = {2025},
volume = {117},
number = {2},
doi = {10.1093/jleuko/qiae144}
}
EUVIMED